Why did BCTX report zero EPS for Q3 2023?

BriaCell Therapeutics (BCTX) reported zero EPS for Q3 2023 due to a strategic move involving a spin-off of its subsidiary, BriaPro Therapeutics Corp. This spin-off was closed on August 31, 2023, and was aimed at accelerating cancer drug development. The spin-off likely necessitated a realignment of financial reporting and resources, which could have temporarily impacted the company's earnings. Such a move is consistent with the company's focus on streamlining its operations and prioritizing its core therapeutic candidates, particularly Bria-IMT and Bria-OTS, which are in advanced stages of clinical development for immunotherapy in breast cancer.